Acuta Capital Partners, LLC
Acuta Capital Partners, LLC reported 23 holdings worth US$143M as of Jun 30, 2026 (Form 13F)
As of Jun 30, 2026 · Filed Aug 14, 2026
Acuta Capital Partners, LLC reported 23 holdings worth US$143M as of Jun 30, 2026. Largest: Praxis Precision Medicines, Inc., Whitehawk Therapeutics, Inc. and Tango Therapeutics, Inc. Filed Aug 14, 2026 (Form 13F).
- Holdings
- 23
- Value as reported
- US$143M
The filing in full
| Company | Shares | Value as reported | % of portfolio |
|---|
| Praxis Precision Medicines, Inc. | 82,796 | US$27.7M | 19.3% |
| Whitehawk Therapeutics, Inc. | 4.69M | US$21.5M | 15.0% |
| Tango Therapeutics, Inc. | 391K | US$12.2M | 8.5% |
| Sutro Biopharma, Inc. | 270K | US$8.97M | 6.3% |
| Arrivent Biopharma, Inc. | 219K | US$7.6M | 5.3% |
| 4d Molecular Therapeutics, Inc. | 508K | US$6.75M | 4.7% |
| Bright Minds Biosciences Inc. | 92,745 | US$6.51M | 4.5% |
| Ocular Therapeutix, Inc. | 532K | US$5.23M | 3.6% |
| Erasca, Inc. | 265K | US$4.86M | 3.4% |
| Surrozen, Inc. | 173K | US$4.5M | 3.1% |
| Argenx Se | 4,705 | US$4.37M | 3.0% |
| Design Therapeutics, Inc. | 283K | US$4.09M | 2.8% |
| Minerva Neurosciences, Inc | 710K | US$3.94M | 2.7% |
| Taysha Gene Therapies, Inc. | 562K | US$3.83M | 2.7% |
| Avalyn Pharma Inc. | 115K | US$3.79M | 2.6% |
| Avalo Therapeutics, Inc. | 186K | US$3.44M | 2.4% |
| Amylyx Pharmaceuticals, Inc. | 168K | US$3.02M | 2.1% |
| Artiva Biotherapeutics, Inc. | 260K | US$2.53M | 1.8% |
| Compass Therapeutics, Inc. | 595K | US$1.3M | 0.91% |
| United Therapeutics Corporation | 2,224 | US$1.21M | 0.84% |
| Contineum Therapeutics, Inc. | 63,095 | US$1.03M | 0.72% |
| Lb Pharmaceuticals Inc | 28,919 | US$939K | 0.65% |
| Maze Therapeutics, Inc. | 0 | US$0 | 0.00% |
| Revolution Medicines, Inc. | 0 | US$0 | 0.00% |
| Terns Pharmaceuticals, Inc. | 0 | US$0 | 0.00% |
| Unicycive Therapeutics, Inc. | 0 | US$0 | 0.00% |
| Entrada Therapeutics, Inc. | 0 | US$0 | 0.00% |
| Ideaya Biosciences, Inc. | 0 | US$0 | 0.00% |
Source
View original at SEC
Related